<!DOCTYPE html>
<html lang="en" dir="ltr">
    <head>
        <meta charset="utf-8">
        <link rel="stylesheet" href="uslm.css">
        <link rel="stylesheet" href="style.css">
        <script lang="text/javascript" src="omni.js" defer></script>

        <!-- Table of Contents button section sheet. Would ideally be a working breadcrumb --> 
        <ul class="breadcrumb" style="text-align:center">
            <!-- TODO GENERALIZE THIS --> 
            <li><a href="index.html"> Table of Contents</a></li>
            
                <li> Division A </a></li>
            
                <li> Title III </a></li>
            
                <li> Subtitle F </a></li>
            
                <li> Part I </a></li>
            
                <li> Section 3851 </a></li>
            
        </ul>


        <title> Omnibuster Section </title>

    </head>

    <body>
        <div class="section">
            <h1> Section s3851 </h1>
            <div class="buttons">
                <div>
                    <button onclick="highlightSelection();">Highlight Text</button>
                </div>
                <div>
                    <button onclick="annotateSelection();">[Not working] Annotate Text</button>
                </div>
            </div>
            <p> <section id="d3355e25453" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851" style="-uslm-lc:I650144"><num value="3851">SEC. 3851. </num><heading>REGULATION OF CERTAIN NONPRESCRIPTION DRUGS THAT ARE MARKETED WITHOUT AN APPROVED DRUG APPLICATION.</heading><subsection class="indent0 fontsize10" id="d3355e25458" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/a" role="instruction" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="a">(a) </num><heading><inline class="small-caps">In General</inline>.—</heading><content>Chapter V of the Federal Food, Drug, and Cosmetic Act <amendingAction type="amend">is amended</amendingAction> by <amendingAction type="insert">inserting</amendingAction> after section 505F of such Act (<a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section355g&amp;num=0&amp;edition=prelim" target="_blank"><ref href="/us/usc/t21/s355g">21 U.S.C. 355g</ref></a>) the following:<quotedContent><section style="-uslm-lc:I650144"><num class="bold " value="505G">“SEC. 505G. </num><heading class="bold ">REGULATION OF CERTAIN NONPRESCRIPTION DRUGS THAT ARE MARKETED WITHOUT AN APPROVED DRUG APPLICATION.</heading><subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="a">“(a) </num><heading><inline class="small-caps">Nonprescription Drugs Marketed Without an Approved Application</inline>.—</heading><chapeau>Nonprescription drugs marketed without an approved drug application under section 505, as of the date of the enactment of this section, shall be treated in accordance with this subsection.</chapeau><paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">“(1) </num><heading><inline class="small-caps">Drugs subject to a final monograph; category i drugs subject to a tentative final monograph</inline>.—</heading><chapeau>A drug is deemed to be generally recognized as safe and effective under section 201(p)(1), not a new drug under section 201(p), and not subject to section 503(b)(1), if—</chapeau><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><chapeau>the drug is—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>in conformity with the requirements for nonprescription use of a final monograph issued under <a href="https://www.law.cornell.edu/cfr/text/21/t330" target="_blank"><ref href="/us/cfr/t21/pt330">part 330 of title 21, Code of Federal Regulations</ref></a> (except as provided in paragraph (2)), the general requirements for nonprescription drugs, and conditions or requirements under subsections (b), (c), and (k); and</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>except as permitted by an order issued under subsection (b) or, in the case of a minor change in the drug, in conformity with an order issued under subsection (c), in a dosage form that, immediately prior to the date of the enactment of this section, has been used to a material extent and for a material time under section 201(p)(2); or</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><chapeau>the drug is—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>classified in category I for safety and effectiveness under a tentative final monograph that is the most recently applicable proposal or determination issued under <a href="https://www.law.cornell.edu/cfr/text/21/t330" target="_blank"><ref href="/us/cfr/t21/pt330">part 330 of title 21, Code of Federal Regulations</ref></a>;</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>in conformity with the proposed requirements for nonprescription use of such tentative final monograph, any applicable subsequent determination by the Secretary, the general requirements for nonprescription drugs, and conditions or requirements under subsections (b), (c), and (k); and</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iii">“(iii) </num><content>except as permitted by an order issued under subsection (b) or, in the case of a minor change in the drug, in conformity with an order issued under subsection (c), in a dosage form that, immediately prior to the date of the enactment of this section, has been used to a material extent and for a material time under section 201(p)(2).</content>
</clause>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">“(2) </num><heading><inline class="small-caps">Treatment of sunscreen drugs</inline>.—</heading><content>With respect to sunscreen drugs subject to this section, the applicable requirements in terms of conformity with a final monograph, for purposes of paragraph (1)(A)(i), shall be the requirements specified in <a href="https://www.law.cornell.edu/cfr/text/21/t352" target="_blank"><ref href="/us/cfr/t21/pt352">part 352 of title 21, Code of Federal Regulations</ref></a>, as published on May 21, 1999, beginning on page 27687 of volume 64 of the Federal Register, except that the applicable requirements governing effectiveness and labeling shall be those specified in <a href="https://www.law.cornell.edu/cfr/text/21/201.327" target="_blank"><ref href="/us/cfr/t21/s201.327">section 201.327 of title 21, Code of Federal Regulations</ref></a>.</content>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="3">“(3) </num><heading><inline class="small-caps">Category iii drugs subject to a tentative final monograph; category i drugs subject to proposed monograph or advance notice of proposed rulemaking</inline>.—</heading><chapeau>A drug that is not described in paragraph (1), (2), or (4) is not required to be the subject of an application approved under section 505, and is not subject to section 503(b)(1), if—</chapeau><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><chapeau>the drug is—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>classified in category III for safety or effectiveness in the preamble of a proposed rule establishing a tentative final monograph that is the most recently applicable proposal or determination for such drug issued under <a href="https://www.law.cornell.edu/cfr/text/21/t330" target="_blank"><ref href="/us/cfr/t21/pt330">part 330 of title 21, Code of Federal Regulations</ref></a>;</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><chapeau>in conformity with—</chapeau><subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><content>the conditions of use, including indication and dosage strength, if any, described for such category III drug in such preamble or in an applicable subsequent proposed rule;</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II) </num><content>the proposed requirements for drugs classified in such tentative final monograph in category I in the most recently proposed rule establishing requirements related to such tentative final monograph and in any final rule establishing requirements that are applicable to the drug; and</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="III">“(III) </num><content>the general requirements for nonprescription drugs and conditions or requirements under subsection (b) or (k); and</content>
</subclause>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iii">“(iii) </num><content>in a dosage form that, immediately prior to the date of the enactment of this section, had been used to a material extent and for a material time under section 201(p)(2); or</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><chapeau>the drug is—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>classified in category I for safety and effectiveness under a proposed monograph or advance notice of proposed rulemaking that is the most recently applicable proposal or determination for such drug issued under <a href="https://www.law.cornell.edu/cfr/text/21/t330" target="_blank"><ref href="/us/cfr/t21/pt330">part 330 of title 21, Code of Federal Regulations</ref></a>;</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>in conformity with the requirements for nonprescription use of such proposed monograph or advance notice of proposed rulemaking, any applicable subsequent determination by the Secretary, the general requirements for nonprescription drugs, and conditions or requirements under subsection (b) or (k); and</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iii">“(iii) </num><content>in a dosage form that, immediately prior to the date of the enactment of this section, has been used to a material extent and for a material time under section 201(p)(2).</content>
</clause>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="4">“(4) </num><heading><inline class="small-caps">Category ii drugs deemed new drugs</inline>.—</heading><content>A drug that is classified in category II for safety or effectiveness under a tentative final monograph or that is subject to a determination to be not generally recognized as safe and effective in a proposed rule that is the most recently applicable proposal issued under <a href="https://www.law.cornell.edu/cfr/text/21/t330" target="_blank"><ref href="/us/cfr/t21/pt330">part 330 of title 21, Code of Federal Regulations</ref></a>, shall be deemed to be a new drug under section 201(p), misbranded under section 502(ee), and subject to the requirement for an approved new drug application under section 505 beginning on the day that is 180 calendar days after the date of the enactment of this section, unless, before such day, the Secretary determines that it is in the interest of public health to extend the period during which the drug may be marketed without such an approved new drug application.</content>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="5">“(5) </num><heading><inline class="small-caps">Drugs not grase deemed new drugs</inline>.—</heading><content>A drug that the Secretary has determined not to be generally recognized as safe and effective under section 201(p)(1) under a final determination issued under <a href="https://www.law.cornell.edu/cfr/text/21/t330" target="_blank"><ref href="/us/cfr/t21/pt330">part 330 of title 21, Code of Federal Regulations</ref></a>, shall be deemed to be a new drug under section 201(p), misbranded under section 502(ee), and subject to the requirement for an approved new drug application under section 505.</content>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="6">“(6) </num><heading><inline class="small-caps">Other drugs deemed new drugs</inline>.—</heading><chapeau>Except as provided in subsection (m), a drug is deemed to be a new drug under section 201(p) and misbranded under section 502(ee) if the drug—</chapeau><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><content>is not subject to section 503(b)(1); and</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><content>is not described in paragraph (1), (2), (3), (4), or (5), or subsection (b)(1)(B).</content>
</subparagraph>
</paragraph>
</subsection>
<subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="b">“(b) </num><heading><inline class="small-caps">Administrative Orders</inline>.—</heading><paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">“(1) </num><heading><inline class="small-caps">In general</inline>.—</heading><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><heading><inline class="small-caps">Determination</inline>.—</heading><chapeau>The Secretary may, on the initiative of the Secretary or at the request of one or more requestors, issue an administrative order determining whether there are conditions under which a specific drug, a class of drugs, or a combination of drugs, is determined to be—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>not subject to section 503(b)(1); and</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>generally recognized as safe and effective under section 201(p)(1).</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><heading><inline class="small-caps">Effect</inline>.—</heading><chapeau>A drug or combination of drugs shall be deemed to not require approval under section 505 if such drug or combination of drugs—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>is determined by the Secretary to meet the conditions specified in clauses (i) and (ii) of subparagraph (A);</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>is marketed in conformity with an administrative order under this subsection;</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iii">“(iii) </num><content>meets the general requirements for nonprescription drugs; and</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iv">“(iv) </num><content>meets the requirements under subsections (c) and (k).</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="C">“(C) </num><heading><inline class="small-caps">Standard</inline>.—</heading><chapeau>The Secretary shall find that a drug is not generally recognized as safe and effective under section 201(p)(1) if—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>the evidence shows that the drug is not generally recognized as safe and effective under section 201(p)(1); or</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>the evidence is inadequate to show that the drug is generally recognized as safe and effective under section 201(p)(1).</content>
</clause>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">“(2) </num><heading><inline class="small-caps">Administrative orders initiated by the secretary</inline>.—</heading><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><heading><inline class="small-caps">In general</inline>.—</heading><chapeau>In issuing an administrative order under paragraph (1) upon the Secretary’s initiative, the Secretary shall—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>make reasonable efforts to notify informally, not later than 2 business days before the issuance of the proposed order, the sponsors of drugs who have a listing in effect under section 510(j) for the drugs or combination of drugs that will be subject to the administrative order;</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><chapeau>after any such reasonable efforts of notification—</chapeau><subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><content>issue a proposed administrative order by publishing it on the website of the Food and Drug Administration and include in such order the reasons for the issuance of such order; and</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II) </num><content>publish a notice of availability of such proposed order in the Federal Register;</content>
</subclause>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iii">“(iii) </num><content>except as provided in subparagraph (B), provide for a public comment period with respect to such proposed order of not less than 45 calendar days; and</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iv">“(iv) </num><chapeau>if, after completion of the proceedings specified in clauses (i) through (iii), the Secretary determines that it is appropriate to issue a final administrative order—</chapeau><subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><content>issue the final administrative order, together with a detailed statement of reasons, which order shall not take effect until the time for requesting judicial review under paragraph (3)(D)(ii) has expired;</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II) </num><content>publish a notice of such final administrative order in the Federal Register;</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="III">“(III) </num><content>afford requestors of drugs that will be subject to such order the opportunity for formal dispute resolution up to the level of the Director of the Center for Drug Evaluation and Research, which initially must be requested within 45 calendar days of the issuance of the order, and, for subsequent levels of appeal, within 30 calendar days of the prior decision; and</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="IV">“(IV) </num><content>except with respect to drugs described in paragraph (3)(B), upon completion of the formal dispute resolution procedure, inform the persons which sought such dispute resolution of their right to request a hearing.</content>
</subclause>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><heading><inline class="small-caps">Exceptions</inline>.—</heading><chapeau>When issuing an administrative order under paragraph (1) on the Secretary’s initiative proposing to determine that a drug described in subsection (a)(3) is not generally recognized as safe and effective under section 201(p)(1), the Secretary shall follow the procedures in subparagraph (A), except that—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><chapeau>the proposed order shall include notice of—</chapeau><subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><content>the general categories of data the Secretary has determined necessary to establish that the drug is generally recognized as safe and effective under section 201(p)(1); and</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II) </num><content>the format for submissions by interested persons;</content>
</subclause>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>the Secretary shall provide for a public comment period of no less than 180 calendar days with respect to such proposed order, except when the Secretary determines, for good cause, that a shorter period is in the interest of public health; and</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iii">“(iii) </num><content>any person who submits data in such comment period shall include a certification that the person has submitted all evidence created, obtained, or received by that person that is both within the categories of data identified in the proposed order and relevant to a determination as to whether the drug is generally recognized as safe and effective under section 201(p)(1).</content>
</clause>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="3">“(3) </num><heading><inline class="small-caps">Hearings; judicial review</inline>.—</heading><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><heading><inline class="small-caps">In general</inline>.—</heading><content>Only a person who participated in each stage of formal dispute resolution under subclause (III) of paragraph (2)(A)(iv) of an administrative order with respect to a drug may request a hearing concerning a final administrative order issued under such paragraph with respect to such drug. If a hearing is sought, such person must submit a request for a hearing, which shall be based solely on information in the administrative record, to the Secretary not later than 30 calendar days after receiving notice of the final decision of the formal dispute resolution procedure.</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><heading><inline class="small-caps">No hearing required with respect to orders relating to certain drugs</inline>.—</heading><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><heading><inline class="small-caps">In general</inline>.—</heading><chapeau>The Secretary shall not be required to provide notice and an opportunity for a hearing pursuant to paragraph (2)(A)(iv) if the final administrative order involved relates to a drug—</chapeau><subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><content>that is described in subsection (a)(3)(A); and</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II) </num><content>with respect to which no human or non-human data studies relevant to the safety or effectiveness of such drug have been submitted to the administrative record since the issuance of the most recent tentative final monograph relating to such drug.</content>
</subclause>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><heading><inline class="small-caps">Human data studies and non-human data defined</inline>.—</heading><chapeau>In this subparagraph:</chapeau><subclause class="indent4 fontsize10" role="definitions" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><content>The term ‘<term>human data studies</term>’ means clinical trials of safety or effectiveness (including actual use studies), pharmacokinetics studies, or bioavailability studies.</content>
</subclause>
<subclause class="indent4 fontsize10" role="definitions" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II) </num><content>The term ‘<term>non-human data</term>’ means data from testing other than with human subjects which provides information concerning safety or effectiveness.</content>
</subclause>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="C">“(C) </num><heading><inline class="small-caps">Hearing procedures</inline>.—</heading><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><heading><inline class="small-caps">Denial of request for hearing</inline>.—</heading><content>If the Secretary determines that information submitted in a request for a hearing under subparagraph (A) with respect to a final administrative order issued under paragraph (2)(A)(iv) does not identify the existence of a genuine and substantial question of material fact, the Secretary may deny such request. In making such a determination, the Secretary may consider only information and data that are based on relevant and reliable scientific principles and methodologies.</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><heading><inline class="small-caps">Single hearing for multiple related requests</inline>.—</heading><content>If more than one request for a hearing is submitted with respect to the same administrative order under subparagraph (A), the Secretary may direct that a single hearing be conducted in which all persons whose hearing requests were granted may participate.</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iii">“(iii) </num><heading><inline class="small-caps">Presiding officer</inline>.—</heading><chapeau>The presiding officer of a hearing requested under subparagraph (A) shall—</chapeau><subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><content>be designated by the Secretary;</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II) </num><content>not be an employee of the Center for Drug Evaluation and Research; and</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="III">“(III) </num><content>not have been previously involved in the development of the administrative order involved or proceedings relating to that administrative order.</content>
</subclause>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iv">“(iv) </num><heading><inline class="small-caps">Rights of parties to hearing</inline>.—</heading><content>The parties to a hearing requested under subparagraph (A) shall have the right to present testimony, including testimony of expert witnesses, and to cross-examine witnesses presented by other parties. Where appropriate, the presiding officer may require that cross-examination by parties representing substantially the same interests be consolidated to promote efficiency and avoid duplication.</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="v">“(v) </num><heading><inline class="small-caps">Final decision</inline>.—</heading><subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><content>At the conclusion of a hearing requested under subparagraph (A), the presiding officer of the hearing shall issue a decision containing findings of fact and conclusions of law. The decision of the presiding officer shall be final.</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II) </num><content>The final decision may not take effect until the period under subparagraph (D)(ii) for submitting a request for judicial review of such decision expires.</content>
</subclause>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="D">“(D) </num><heading><inline class="small-caps">Judicial review of final administrative order</inline>.—</heading><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><heading><inline class="small-caps">In general</inline>.—</heading><content>The procedures described in section 505(h) shall apply with respect to judicial review of final administrative orders issued under this subsection in the same manner and to the same extent as such section applies to an order described in such section except that the judicial review shall be taken by filing in an appropriate district court of the United States in lieu of the appellate courts specified in such section.</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><heading><inline class="small-caps">Period to submit a request for judicial review</inline>.—</heading><chapeau>A person eligible to request a hearing under this paragraph and seeking judicial review of a final administrative order issued under this subsection shall file such request for judicial review not later than 60 calendar days after the latest of—</chapeau><subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><content>the date on which notice of such order is published;</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II) </num><content>the date on which a hearing with respect to such order is denied under subparagraph (B) or (C)(i);</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="III">“(III) </num><content>the date on which a final decision is made following a hearing under subparagraph (C)(v); or</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="IV">“(IV) </num><content>if no hearing is requested, the date on which the time for requesting a hearing expires.</content>
</subclause>
</clause>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="4">“(4) </num><heading><inline class="small-caps">Expedited procedure with respect to administrative orders initiated by the secretary</inline>.—</heading><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><heading><inline class="small-caps">Imminent hazard to the public health</inline>.—</heading><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><heading><inline class="small-caps">In general</inline>.—</heading><chapeau>In the case of a determination by the Secretary that a drug, class of drugs, or combination of drugs subject to this section poses an imminent hazard to the public health, the Secretary, after first making reasonable efforts to notify, not later than 48 hours before issuance of such order under this subparagraph, sponsors who have a listing in effect under section 510(j) for such drug or combination of drugs—</chapeau><subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><content>may issue an interim final administrative order for such drug, class of drugs, or combination of drugs under paragraph (1), together with a detailed statement of the reasons for such order;</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II) </num><content>shall publish in the Federal Register a notice of availability of any such order; and</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="III">“(III) </num><content>shall provide for a public comment period of at least 45 calendar days with respect to such interim final order.</content>
</subclause>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><heading><inline class="small-caps">Nondelegation</inline>.—</heading><content>The Secretary may not delegate the authority to issue an interim final administrative order under this subparagraph.</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><heading><inline class="small-caps">Safety labeling changes</inline>.—</heading><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><heading><inline class="small-caps">In general</inline>.—</heading><chapeau>In the case of a determination by the Secretary that a change in the labeling of a drug, class of drugs, or combination of drugs subject to this section is reasonably expected to mitigate a significant or unreasonable risk of a serious adverse event associated with use of the drug, the Secretary may—</chapeau><subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><content>make reasonable efforts to notify informally, not later than 48 hours before the issuance of the interim final order, the sponsors of drugs who have a listing in effect under section 510(j) for such drug or combination of drugs;</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II) </num><content>after reasonable efforts of notification, issue an interim final administrative order in accordance with paragraph (1) to require such change, together with a detailed statement of the reasons for such order;</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="III">“(III) </num><content>publish in the Federal Register a notice of availability of such order; and</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="IV">“(IV) </num><content>provide for a public comment period of at least 45 calendar days with respect to such interim final order.</content>
</subclause>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><heading><inline class="small-caps">Content of order</inline>.—</heading><content>An interim final order issued under this subparagraph with respect to the labeling of a drug may provide for new warnings and other information required for safe use of the drug.</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="C">“(C) </num><heading><inline class="small-caps">Effective date</inline>.—</heading><content>An order under subparagraph (A) or (B) shall take effect on a date specified by the Secretary.</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="D">“(D) </num><heading><inline class="small-caps">Final order</inline>.—</heading><chapeau>After the completion of the proceedings in subparagraph (A) or (B), the Secretary shall—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>issue a final order in accordance with paragraph (1);</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>publish a notice of availability of such final administrative order in the Federal Register; and</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iii">“(iii) </num><content>afford sponsors of such drugs that will be subject to such an order the opportunity for formal dispute resolution up to the level of the Director of the Center for Drug Evaluation and Research, which must initially be within 45 calendar days of the issuance of the order, and for subsequent levels of appeal, within 30 calendar days of the prior decision.</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="E">“(E) </num><heading><inline class="small-caps">Hearings</inline>.—</heading><content>A sponsor of a drug subject to a final order issued under subparagraph (D) and that participated in each stage of formal dispute resolution under clause (iii) of such subparagraph may request a hearing on such order. The provisions of subparagraphs (A), (B), and (C) of paragraph (3), other than paragraph (3)(C)(v)(II), shall apply with respect to a hearing on such order in the same manner and to the same extent as such provisions apply with respect to a hearing on an administrative order issued under paragraph (2)(A)(iv).</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="F">“(F) </num><heading><inline class="small-caps">Timing</inline>.—</heading><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><heading><inline class="small-caps">Final order and hearing</inline>.—</heading><chapeau>The Secretary shall—</chapeau><subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><content>not later than 6 months after the date on which the comment period closes under subparagraph (A) or (B), issue a final order in accordance with paragraph (1); and</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II) </num><content>not later than 12 months after the date on which such final order is issued, complete any hearing under subparagraph (E).</content>
</subclause>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><heading><inline class="small-caps">Dispute resolution request</inline>.—</heading><content>The Secretary shall specify in an interim final order issued under subparagraph (A) or (B) such shorter periods for requesting dispute resolution under subparagraph (D)(iii) as are necessary to meet the requirements of this subparagraph.</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="G">“(G) </num><heading><inline class="small-caps">Judicial review</inline>.—</heading><content>A final order issued pursuant to subparagraph (F) shall be subject to judicial review in accordance with paragraph (3)(D).</content>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="5">“(5) </num><heading><inline class="small-caps">Administrative order initiated at the request of a requestor</inline>.—</heading><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><heading><inline class="small-caps">In general</inline>.—</heading><chapeau>In issuing an administrative order under paragraph (1) at the request of a requestor with respect to certain drugs, classes of drugs, or combinations of drugs—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>the Secretary shall, after receiving a request under this subparagraph, determine whether the request is sufficiently complete and formatted to permit a substantive review;</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><chapeau>if the Secretary determines that the request is sufficiently complete and formatted to permit a substantive review, the Secretary shall—</chapeau><subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><content>file the request; and</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II) </num><content>initiate proceedings with respect to issuing an administrative order in accordance with paragraphs (2) and (3); and</content>
</subclause>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iii">“(iii) </num><content>except as provided in paragraph (6), if the Secretary determines that a request does not meet the requirements for filing or is not sufficiently complete and formatted to permit a substantive review, the requestor may demand that the request be filed over protest, and the Secretary shall initiate proceedings to review the request in accordance with paragraph (2)(A).</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><heading><inline class="small-caps">Request to initiate proceedings</inline>.—</heading><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><heading><inline class="small-caps">In general</inline>.—</heading><chapeau>A requestor seeking an administrative order under paragraph (1) with respect to certain drugs, classes of drugs, or combinations of drugs, shall submit to the Secretary a request to initiate proceedings for such order in the form and manner as specified by the Secretary. Such requestor may submit a request under this subparagraph for the issuance of an administrative order—</chapeau><subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><content>determining whether a drug is generally recognized as safe and effective under section 201(p)(1), exempt from section 503(b)(1), and not required to be the subject of an approved application under section 505; or</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II) </num><chapeau>determining whether a change to a condition of use of a drug is generally recognized as safe and effective under section 201(p)(1), exempt from section 503(b)(1), and not required to be the subject of an approved application under section 505, if, absent such a changed condition of use, such drug is—</chapeau><item class="indent5 fontsize10" style="-uslm-lc:I650130"><num style="-uslm-lc:emspace2" value="aa">“(aa) </num><content>generally recognized as safe and effective under section 201(p)(1) in accordance with subsection (a)(1), (a)(2), or an order under this subsection; or</content>
</item>
<item class="indent5 fontsize10" style="-uslm-lc:I650130"><num style="-uslm-lc:emspace2" value="bb">“(bb) </num><content>subject to subsection (a)(3), but only if such requestor initiates such request in conjunction with a request for the Secretary to determine whether such drug is generally recognized as safe and effective under section 201(p)(1), which is filed by the Secretary under subparagraph (A)(ii).</content>
</item>
</subclause>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><heading><inline class="small-caps">Exception</inline>.—</heading><content>The Secretary is not required to complete review of a request for a change described in clause (i)(II) if the Secretary determines that there is an inadequate basis to find the drug is generally recognized as safe and effective under section 201(p)(1) under paragraph (1) and issues a final order announcing that determination.</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iii">“(iii) </num><heading><inline class="small-caps">Withdrawal</inline>.—</heading><content>The requestor may withdraw a request under this paragraph, according to the procedures set forth pursuant to subsection (d)(2)(B). Notwithstanding any other provision of this section, if such request is withdrawn, the Secretary may cease proceedings under this subparagraph.</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="C">“(C) </num><heading><inline class="small-caps">Exclusivity</inline>.—</heading><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><heading><inline class="small-caps">In general</inline>.—</heading><chapeau>A final administrative order issued in response to a request under this section shall have the effect of authorizing solely the order requestor (or the licensees, assignees, or successors in interest of such requestor with respect to the subject of such order), for a period of 18 months following the effective date of such final order and beginning on the date the requestor may lawfully market such drugs pursuant to the order, to market drugs—</chapeau><subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><content>incorporating changes described in clause (ii); and</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II) </num><content>subject to the limitations under clause (iv).</content>
</subclause>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><heading><inline class="small-caps">Changes described</inline>.—</heading><chapeau>A change described in this clause is a change subject to an order specified in clause (i), which—</chapeau><subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><content>provides for a drug to contain an active ingredient (including any ester or salt of the active ingredient) not previously incorporated in a drug described in clause (iii); or</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II) </num><content>provides for a change in the conditions of use of a drug, for which new human data studies conducted or sponsored by the requestor (or for which the requestor has an exclusive right of reference) were essential to the issuance of such order.</content>
</subclause>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iii">“(iii) </num><heading><inline class="small-caps">Drugs described</inline>.—</heading><chapeau>The drugs described in this clause are drugs—</chapeau><subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><content>specified in subsection (a)(1), (a)(2), or (a)(3);</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II) </num><content>subject to a final order issued under this section;</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="III">“(III) </num><content>subject to a final sunscreen order (as defined in section 586(2)(A)); or</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="IV">“(IV) </num><content>described in subsection (m)(1), other than drugs subject to an active enforcement action under chapter III of this Act.</content>
</subclause>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iv">“(iv) </num><heading><inline class="small-caps">Limitations on exclusivity</inline>.—</heading><subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><heading><inline class="small-caps">In general</inline>.—</heading><chapeau>Only one 18-month period under this subparagraph shall be granted, under each order described in clause (i), with respect to changes (to the drug subject to such order) which are either—</chapeau><item class="indent5 fontsize10" style="-uslm-lc:I650130"><num style="-uslm-lc:emspace2" value="aa">“(aa) </num><content>changes described in clause (ii)(I), relating to active ingredients; or</content>
</item>
<item class="indent5 fontsize10" style="-uslm-lc:I650130"><num style="-uslm-lc:emspace2" value="bb">“(bb) </num><content>changes described in clause (ii)(II), relating to conditions of use.</content>
</item>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II) </num><heading><inline class="small-caps">No exclusivity allowed</inline>.—</heading><chapeau>No exclusivity shall apply to changes to a drug which are—</chapeau><item class="indent5 fontsize10" style="-uslm-lc:I650130"><num style="-uslm-lc:emspace2" value="aa">“(aa) </num><content>the subject of a Tier 2 OTC monograph order request (as defined in section 744L);</content>
</item>
<item class="indent5 fontsize10" style="-uslm-lc:I650130"><num style="-uslm-lc:emspace2" value="bb">“(bb) </num><content>safety-related changes, as defined by the Secretary, or any other changes the Secretary considers necessary to assure safe use; or</content>
</item>
<item class="indent5 fontsize10" style="-uslm-lc:I650130"><num style="-uslm-lc:emspace2" value="cc">“(cc) </num><content>changes related to methods of testing safety or efficacy.</content>
</item>
</subclause>
</clause>
<clause class="indent3 fontsize10" role="definitions" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="v">“(v) </num><heading><inline class="small-caps">New human data studies defined</inline>.—</heading><chapeau>In this subparagraph, the term ‘<term>new human data studies</term>’ means clinical trials of safety or effectiveness (including actual use studies), pharmacokinetics studies, or bioavailability studies, the results of which—</chapeau><subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><chapeau>have not been relied on by the Secretary to support—</chapeau><item class="indent5 fontsize10" style="-uslm-lc:I650130"><num style="-uslm-lc:emspace2" value="aa">“(aa) </num><content>a proposed or final determination that a drug described in subclause (I), (II), or (III) of clause (iii) is generally recognized as safe and effective under section 201(p)(1); or</content>
</item>
<item class="indent5 fontsize10" style="-uslm-lc:I650130"><num style="-uslm-lc:emspace2" value="bb">“(bb) </num><content>approval of a drug that was approved under section 505; and</content>
</item>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II) </num><chapeau>do not duplicate the results of another study that was relied on by the Secretary to support—</chapeau><item class="indent5 fontsize10" style="-uslm-lc:I650130"><num style="-uslm-lc:emspace2" value="aa">“(aa) </num><content>a proposed or final determination that a drug described in subclause (I), (II), or (III) of clause (iii) is generally recognized as safe and effective under section 201(p)(1); or</content>
</item>
<item class="indent5 fontsize10" style="-uslm-lc:I650130"><num style="-uslm-lc:emspace2" value="bb">“(bb) </num><content>approval of a drug that was approved under section 505.</content>
</item>
</subclause>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="vi">“(vi) </num><heading><inline class="small-caps">Notification of drug not available for sale</inline>.—</heading><chapeau>A requestor that is granted exclusivity with respect to a drug under this subparagraph shall notify the Secretary in writing within 1 year of the issuance of the final administrative order if the drug that is the subject of such order will not be available for sale within 1 year of the date of issuance of such order. The requestor shall include with such notice the—</chapeau><subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><content>identity of the drug by established name and by proprietary name, if any;</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II) </num><content>strength of the drug;</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="III">“(III) </num><content>date on which the drug will be available for sale, if known; and</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="IV">“(IV) </num><content>reason for not marketing the drug after issuance of the order.</content>
</subclause>
</clause>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="6">“(6) </num><heading><inline class="small-caps">Information regarding safe nonprescription marketing and use as condition for filing a generally recognized as safe and effective request</inline>.—</heading><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><heading><inline class="small-caps">In general</inline>.—</heading><chapeau>In response to a request under this section that a drug described in subparagraph (B) be generally recognized as safe and effective, the Secretary—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>may file such request, if the request includes information specified under subparagraph (C) with respect to safe nonprescription marketing and use of such drug; or</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>if the request fails to include information specified under subparagraph (C), shall refuse to file such request and require that nonprescription marketing of the drug be pursuant to a new drug application as described in subparagraph (D).</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><heading><inline class="small-caps">Drug described</inline>.—</heading><chapeau>A drug described in this subparagraph is a nonprescription drug which contains an active ingredient not previously incorporated in a drug—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>specified in subsection (a)(1), (a)(2), or (a)(3);</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>subject to a final order under this section; or</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iii">“(iii) </num><content>subject to a final sunscreen order (as defined in section 586(2)(A)).</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="C">“(C) </num><heading><inline class="small-caps">Information demonstrating prima facie safe nonprescription marketing and use</inline>.—</heading><chapeau>Information specified in this subparagraph, with respect to a request described in subparagraph (A)(i), is—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>information sufficient for a prima facie demonstration that the drug subject to such request has a verifiable history of being marketed and safely used by consumers in the United States as a nonprescription drug under comparable conditions of use;</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><chapeau>if the drug has not been previously marketed in the United States as a nonprescription drug, information sufficient for a prima facie demonstration that the drug was marketed and safely used under comparable conditions of marketing and use in a country listed in section 802(b)(1)(A) or designated by the Secretary in accordance with section 802(b)(1)(B)—</chapeau><subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><content>for such period as needed to provide reasonable assurances concerning the safe nonprescription use of the drug; and</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II) </num><content>during such time was subject to sufficient monitoring by a regulatory body considered acceptable by the Secretary for such monitoring purposes, including for adverse events associated with nonprescription use of the drug; or</content>
</subclause>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iii">“(iii) </num><content>if the Secretary determines that information described in clause (i) or (ii) is not needed to provide a prima facie demonstration that the drug can be safely marketed and used as a nonprescription drug, such other information the Secretary determines is sufficient for such purposes.</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="D">“(D) </num><heading><inline class="small-caps">Marketing pursuant to new drug application</inline>.—</heading><chapeau>In the case of a request described in subparagraph (A)(ii), the drug subject to such request may be resubmitted for filing only if—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>the drug is marketed as a nonprescription drug, under conditions of use comparable to the conditions specified in the request, for such period as the Secretary determines appropriate (not to exceed 5 consecutive years) pursuant to an application approved under section 505; and</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>during such period, 1,000,000 retail packages of the drug, or an equivalent quantity as determined by the Secretary, were distributed for retail sale, as determined in such manner as the Secretary finds appropriate.</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="E">“(E) </num><heading><inline class="small-caps">Rule of application</inline>.—</heading><content>Except in the case of a request involving a drug described in section 586(9), as in effect on January 1, 2017, if the Secretary refuses to file a request under this paragraph, the requestor may not file such request over protest under paragraph (5)(A)(iii).</content>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="7">“(7) </num><heading><inline class="small-caps">Packaging</inline>.—</heading><content>An administrative order issued under paragraph (2), (4)(A), or (5) may include requirements for the packaging of a drug to encourage use in accordance with labeling. Such requirements may include unit dose packaging, requirements for products intended for use by pediatric populations, requirements to reduce risk of harm from unsupervised ingestion, and other appropriate requirements. This paragraph does not authorize the Food and Drug Administration to require standards or testing procedures as described in <a href="https://www.law.cornell.edu/cfr/text/16/t1700" target="_blank"><ref href="/us/cfr/t16/pt1700">part 1700 of title 16, Code of Federal Regulations</ref></a>.</content>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="8">“(8) </num><heading><inline class="small-caps">Final and tentative final monographs for category i drugs deemed final administrative orders</inline>.—</heading><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><heading><inline class="small-caps">In general</inline>.—</heading><content>A final monograph or tentative final monograph described in subparagraph (B) shall be deemed to be a final administrative order under this subsection and may be amended, revoked, or otherwise modified in accordance with the procedures of this subsection.</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><heading><inline class="small-caps">Monographs described</inline>.—</heading><chapeau>For purposes of subparagraph (A), a final monograph or tentative final monograph is described in this subparagraph if it—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>establishes conditions of use for a drug described in paragraph (1) or (2) of subsection (a); and</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>represents the most recently promulgated version of such conditions, including as modified, in whole or in part, by any proposed or final rule.</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="C">“(C) </num><heading><inline class="small-caps">Deemed orders include harmonizing technical amendments</inline>.—</heading><content>The deemed establishment of a final administrative order under subparagraph (A) shall be construed to include any technical amendments to such order as the Secretary determines necessary to ensure that such order is appropriately harmonized, in terms of terminology or cross-references, with the applicable provisions of this Act (and regulations thereunder) and any other orders issued under this section.</content>
</subparagraph>
</paragraph>
</subsection>
<subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="c">“(c) </num><heading><inline class="small-caps">Procedure for Minor Changes</inline>.—</heading><paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">“(1) </num><heading><inline class="small-caps">In general</inline>.—</heading><chapeau>Minor changes in the dosage form of a drug that is described in paragraph (1) or (2) of subsection (a) or the subject of an order issued under subsection (b) may be made by a requestor without the issuance of an order under subsection (b) if—</chapeau><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><chapeau>the requestor maintains such information as is necessary to demonstrate that the change—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>will not affect the safety or effectiveness of the drug; and</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>will not materially affect the extent of absorption or other exposure to the active ingredient in comparison to a suitable reference product; and</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><content>the change is in conformity with the requirements of an applicable administrative order issued by the Secretary under paragraph (3).</content>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">“(2) </num><heading><inline class="small-caps">Additional information</inline>.—</heading><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><heading><inline class="small-caps">Access to records</inline>.—</heading><content>A sponsor shall submit records requested by the Secretary relating to such a minor change under section 704(a)(4), within 15 business days of receiving such a request, or such longer period as the Secretary may provide.</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><heading><inline class="small-caps">Insufficient information</inline>.—</heading><chapeau>If the Secretary determines that the information contained in such records is not sufficient to demonstrate that the change does not affect the safety or effectiveness of the drug or materially affect the extent of absorption or other exposure to the active ingredient, the Secretary—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>may so inform the sponsor of the drug in writing; and</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>if the Secretary so informs the sponsor, shall provide the sponsor of the drug with a reasonable opportunity to provide additional information.</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="C">“(C) </num><heading><inline class="small-caps">Failure to submit sufficient information</inline>.—</heading><chapeau>If the sponsor fails to provide such additional information within a time prescribed by the Secretary, or if the Secretary determines that such additional information does not demonstrate that the change does not—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>affect the safety or effectiveness of the drug; or</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>materially affect the extent of absorption or other exposure to the active ingredient in comparison to a suitable reference product,</content>
</clause>
<continuation class="indent2 fontsize10" style="-uslm-lc:I650124">the drug as modified is a new drug under section 201(p) and shall be deemed to be misbranded under section 502(ee).</continuation>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="3">“(3) </num><heading><inline class="small-caps">Determining whether a change will affect safety or effectiveness</inline>.—</heading><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><heading><inline class="small-caps">In general</inline>.—</heading><content>The Secretary shall issue one or more administrative orders specifying requirements for determining whether a minor change made by a sponsor pursuant to this subsection will affect the safety or effectiveness of a drug or materially affect the extent of absorption or other exposure to an active ingredient in the drug in comparison to a suitable reference product, together with guidance for applying those orders to specific dosage forms.</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><heading><inline class="small-caps">Standard practices</inline>.—</heading><content>The orders and guidance issued by the Secretary under subparagraph (A) shall take into account relevant public standards and standard practices for evaluating the quality of drugs, and may take into account the special needs of populations, including children.</content>
</subparagraph>
</paragraph>
</subsection>
<subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="d">“(d) </num><heading><inline class="small-caps">Confidentiality of Information Submitted to the Secretary</inline>.—</heading><paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">“(1) </num><heading><inline class="small-caps">In general</inline>.—</heading><content>Subject to paragraph (2), any information, including reports of testing conducted on the drug or drugs involved, that is submitted by a requestor in connection with proceedings on an order under this section (including any minor change under subsection (c)) and is a trade secret or confidential information subject to <a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title5-section552&amp;num=0&amp;edition=prelim" target="_blank"><ref href="/us/usc/t5/s552/b/4">section 552(b)(4) of title 5, United States Code</ref></a>, or <a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title18-section1905&amp;num=0&amp;edition=prelim" target="_blank"><ref href="/us/usc/t18/s1905">section 1905 of title 18, United States Code</ref></a>, shall not be disclosed to the public unless the requestor consents to that disclosure.</content>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">“(2) </num><heading><inline class="small-caps">Public availability</inline>.—</heading><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><heading><inline class="small-caps">In general</inline>.—</heading><chapeau>Except as provided in subparagraph (B), the Secretary shall—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>make any information submitted by a requestor in support of a request under subsection (b)(5)(A) available to the public not later than the date on which the proposed order is issued; and</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>make any information submitted by any other person with respect to an order requested (or initiated by the Secretary) under subsection (b), available to the public upon such submission.</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><heading><inline class="small-caps">Limitations on public availability</inline>.—</heading><chapeau>Information described in subparagraph (A) shall not be made public if—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>the information pertains to pharmaceutical quality information, unless such information is necessary to establish standards under which a drug is generally recognized as safe and effective under section 201(p)(1);</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>the information is submitted in a requestor-initiated request, but the requestor withdraws such request, in accordance with withdrawal procedures established by the Secretary, before the Secretary issues the proposed order;</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iii">“(iii) </num><content>the Secretary requests and obtains the information under subsection (c) and such information is not submitted in relation to an order under subsection (b); or</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iv">“(iv) </num><content>the information is of the type contained in raw datasets.</content>
</clause>
</subparagraph>
</paragraph>
</subsection>
<subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="e">“(e) </num><heading><inline class="small-caps">Updates to Drug Listing Information</inline>.—</heading><content>A sponsor who makes a change to a drug subject to this section shall submit updated drug listing information for the drug in accordance with section 510(j) within 30 calendar days of the date when the drug is first commercially marketed, except that a sponsor who was the order requestor with respect to an order subject to subsection (b)(5)(C) (or a licensee, assignee, or successor in interest of such requestor) shall submit updated drug listing information on or before the date when the drug is first commercially marketed.</content>
</subsection>
<subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="f">“(f) </num><heading><inline class="small-caps">Approvals Under Section 505</inline>.—</heading><content>The provisions of this section shall not be construed to preclude a person from seeking or maintaining the approval of an application for a drug under sections 505(b)(1), 505(b)(2), and 505(j). A determination under this section that a drug is not subject to section 503(b)(1), is generally recognized as safe and effective under section 201(p)(1), and is not a new drug under section 201(p) shall constitute a finding that the drug is safe and effective that may be relied upon for purposes of an application under section 505(b)(2), so that the applicant shall be required to submit for purposes of such application only information needed to support any modification of the drug that is not covered by such determination under this section.</content>
</subsection>
<subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="g">“(g) </num><heading><inline class="small-caps">Public Availability of Administrative Orders</inline>.—</heading><chapeau>The Secretary shall establish, maintain, update (as determined necessary by the Secretary but no less frequently than annually), and make publicly available, with respect to orders issued under this section—</chapeau><paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">“(1) </num><content>a repository of each final order and interim final order in effect, including the complete text of the order; and</content>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">“(2) </num><chapeau>a listing of all orders proposed and under development under subsection (b)(2), including—</chapeau><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><content>a brief description of each such order; and</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><content>the Secretary’s expectations, if resources permit, for issuance of proposed orders over a 3-year period.</content>
</subparagraph>
</paragraph>
</subsection>
<subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="h">“(h) </num><heading><inline class="small-caps">Development Advice to Sponsors or Requestors</inline>.—</heading><content>The Secretary shall establish procedures under which sponsors or requestors may meet with appropriate officials of the Food and Drug Administration to obtain advice on the studies and other information necessary to support submissions under this section and other matters relevant to the regulation of nonprescription drugs and the development of new nonprescription drugs under this section.</content>
</subsection>
<subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="i">“(i) </num><heading><inline class="small-caps">Participation of Multiple Sponsors or Requestors</inline>.—</heading><content>The Secretary shall establish procedures to facilitate efficient participation by multiple sponsors or requestors in proceedings under this section, including provision for joint meetings with multiple sponsors or requestors or with organizations nominated by sponsors or requestors to represent their interests in a proceeding.</content>
</subsection>
<subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="j">“(j) </num><heading><inline class="small-caps">Electronic Format</inline>.—</heading><content>All submissions under this section shall be in electronic format.</content>
</subsection>
<subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="k">“(k) </num><heading><inline class="small-caps">Effect on Existing Regulations Governing Nonprescription Drugs</inline>.—</heading><paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">“(1) </num><heading><inline class="small-caps">Regulations of general applicability to nonprescription drugs</inline>.—</heading><content>Except as provided in this subsection, nothing in this section supersedes regulations establishing general requirements for nonprescription drugs, including regulations of general applicability contained in parts 201, 250, and 330 of <ref href="/us/cfr/t21">title 21, Code of Federal Regulations</ref>, or any successor regulations. The Secretary shall establish or modify such regulations by means of rulemaking in accordance with <a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title5-section553&amp;num=0&amp;edition=prelim" target="_blank"><ref href="/us/usc/t5/s553">section 553 of title 5, United States Code</ref></a>.</content>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">“(2) </num><heading><inline class="small-caps">Regulations establishing requirements for specific nonprescription drugs</inline>.—</heading><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><content>The provisions of <a href="https://www.law.cornell.edu/cfr/text/21/310.545" target="_blank"><ref href="/us/cfr/t21/s310.545">section 310.545 of title 21, Code of Federal Regulations</ref></a>, as in effect on the day before the date of the enactment of this section, shall be deemed to be a final order under subsection (b).</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><chapeau>Regulations in effect on the day before the date of the enactment of this section, establishing requirements for specific nonprescription drugs marketed pursuant to this section (including such requirements in parts 201 and 250 of <ref href="/us/cfr/t21">title 21, Code of Federal Regulations</ref>), shall be deemed to be final orders under subsection (b), only as they apply to drugs—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>subject to paragraph (1), (2), (3), or (4) of subsection (a); or</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>otherwise subject to an order under this section.</content>
</clause>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="3">“(3) </num><heading><inline class="small-caps">Withdrawal of regulations</inline>.—</heading><content>The Secretary shall withdraw regulations establishing final monographs and the procedures governing the over-the-counter drug review under part 330 and other relevant parts of <ref href="/us/cfr/t21">title 21, Code of Federal Regulations</ref> (as in effect on the day before the date of the enactment of this section), or make technical changes to such regulations to ensure conformity with appropriate terminology and cross references. Notwithstanding <a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title5-sectionh5&amp;num=0&amp;edition=prelim" target="_blank"><ref href="/us/usc/t5/ch5/schII">subchapter II of chapter 5 of title 5, United States Code</ref></a>, any such withdrawal or technical changes shall be made without public notice and comment and shall be effective upon publication through notice in the Federal Register (or upon such date as specified in such notice).</content>
</paragraph>
</subsection>
<subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="l">“(l) </num><heading><inline class="small-caps">Guidance</inline>.—</heading><chapeau>The Secretary shall issue guidance that specifies—</chapeau><paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">“(1) </num><content>the procedures and principles for formal meetings between the Secretary and sponsors or requestors for drugs subject to this section;</content>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">“(2) </num><content>the format and content of data submissions to the Secretary under this section;</content>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="3">“(3) </num><content>the format of electronic submissions to the Secretary under this section;</content>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="4">“(4) </num><content>consolidated proceedings for appeal and the procedures for such proceedings where appropriate; and</content>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="5">“(5) </num><content>for minor changes in drugs, recommendations on how to comply with the requirements in orders issued under subsection (c)(3).</content>
</paragraph>
</subsection>
<subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="m">“(m) </num><heading><inline class="small-caps">Rule of Construction</inline>.—</heading><paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">“(1) </num><heading><inline class="small-caps">In general</inline>.—</heading><chapeau>This section shall not affect the treatment or status of a nonprescription drug—</chapeau><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><content>that is marketed without an application approved under section 505 as of the date of the enactment of this section;</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><content>that is not subject to an order issued under this section; and</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="C">“(C) </num><content>to which paragraph (1), (2), (3), (4), or (5) of subsection (a) do not apply.</content>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">“(2) </num><heading><inline class="small-caps">Treatment of products previously found to be subject to time and extent requirements</inline>.—</heading><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><content>Notwithstanding subsection (a), a drug described in subparagraph (B) may only be lawfully marketed, without an application approved under section 505, pursuant to an order issued under this section.</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><content>A drug described in this subparagraph is a drug which, prior to the date of the enactment of this section, the Secretary determined in a proposed or final rule to be ineligible for review under the OTC drug review (as such phrase ‘OTC drug review’ was used in <a href="https://www.law.cornell.edu/cfr/text/21/330.14" target="_blank"><ref href="/us/cfr/t21/s330.14">section 330.14 of title 21, Code of Federal Regulations</ref></a>, as in effect on the day before the date of the enactment of this section).</content>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="3">“(3) </num><heading><inline class="small-caps">Preservation of authority</inline>.—</heading><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><content>Nothing in paragraph (1) shall be construed to preclude or limit the applicability of any provision of this Act other than this section.</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><content>Nothing in subsection (a) shall be construed to prohibit the Secretary from issuing an order under this section finding a drug to be not generally recognized as safe and effective under section 201(p)(1), as the Secretary determines appropriate.</content>
</subparagraph>
</paragraph>
</subsection>
<subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="n">“(n) </num><heading><inline class="small-caps">Investigational New Drugs</inline>.—</heading><content>A drug is not subject to this section if an exemption for investigational use under section 505(i) is in effect for such drug.</content>
</subsection>
<subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="o">“(o) </num><heading><inline class="small-caps">Inapplicability of Paperwork Reduction Act</inline>.—</heading><content><a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title44-sectionh35&amp;num=0&amp;edition=prelim" target="_blank"><ref href="/us/usc/t44/ch35">Chapter 35 of title 44, United States Code</ref></a>, shall not apply to collections of information made under this section.</content>
</subsection>
<subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="p">“(p) </num><heading><inline class="small-caps">Inapplicability of Notice and Comment Rulemaking and Other Requirements</inline>.—</heading><content>The requirements of subsection (b) shall apply with respect to orders issued under this section instead of the requirements of <a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title5-sectionh5&amp;num=0&amp;edition=prelim" target="_blank"><ref href="/us/usc/t5/ch5/schII">subchapter II of chapter 5 of title 5, United States Code</ref></a>.</content>
</subsection>
<subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="q">“(q) </num><heading><inline class="small-caps">Definitions</inline>.—</heading><chapeau>In this section:</chapeau><paragraph class="indent1 fontsize10" role="definitions" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">“(1) </num><content>The term ‘<term>nonprescription drug</term>’ refers to a drug not subject to the requirements of section 503(b)(1).</content>
</paragraph>
<paragraph class="indent1 fontsize10" role="definitions" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">“(2) </num><chapeau>The term ‘<term>sponsor</term>’ refers to any person marketing, manufacturing, or processing a drug that—</chapeau><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><content>is listed pursuant to section 510(j); and</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><content>is or will be subject to an administrative order under this section of the Food and Drug Administration.</content>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" role="definitions" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="3">“(3) </num><content>The term ‘<term>requestor</term>’ refers to any person or group of persons marketing, manufacturing, processing, or developing a drug.”</content>
</paragraph>
</subsection>
</section>
</quotedContent>.</content>
</subsection>
<subsection class="indent0 fontsize10" id="d3355e27607" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/b" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="b">(b) </num><heading><inline class="small-caps">GAO Study</inline>.—</heading><chapeau>Not later than 4 years after the date of enactment of this Act, the Comptroller General of the United States shall submit a study to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate addressing the effectiveness and overall impact of exclusivity under section 505G of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a), and section 586C of such Act (<a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360fff–3&amp;num=0&amp;edition=prelim" target="_blank"><ref href="/us/usc/t21/s360fff–3">21 U.S.C. 360fff–3</ref></a>), including the impact of such exclusivity on consumer access. Such study shall include—</chapeau><paragraph class="indent1 fontsize10" id="d3355e27619" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/b/1" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">(1) </num><chapeau>an analysis of the impact of exclusivity under such section 505G for nonprescription drug products, including—</chapeau><subparagraph class="indent2 fontsize10" id="d3355e27624" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/b/1/A" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">(A) </num><content>the number of nonprescription drug products that were granted exclusivity and the indication for which the nonprescription drug products were determined to be generally recognized as safe and effective;</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" id="d3355e27631" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/b/1/B" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">(B) </num><chapeau>whether the exclusivity for such drug products was granted for—</chapeau><clause class="indent3 fontsize10" id="d3355e27636" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/b/1/B/i" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">(i) </num><content>a new active ingredient (including any ester or salt of the active ingredient); or</content>
</clause>
<clause class="indent3 fontsize10" id="d3355e27643" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/b/1/B/ii" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">(ii) </num><content>changes in the conditions of use of a drug, for which new human data studies conducted or sponsored by the requestor were essential;</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" id="d3355e27651" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/b/1/C" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="C">(C) </num><content>whether, and to what extent, the exclusivity impacted the requestor’s or sponsor’s decision to develop the drug product;</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" id="d3355e27658" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/b/1/D" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="D">(D) </num><chapeau>an analysis of the implementation of the exclusivity provision in such section 505G, including—</chapeau><clause class="indent3 fontsize10" id="d3355e27663" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/b/1/D/i" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">(i) </num><content>the resources used by the Food and Drug Administration;</content>
</clause>
<clause class="indent3 fontsize10" id="d3355e27670" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/b/1/D/ii" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">(ii) </num><content>the impact of such provision on innovation, as well as research and development in the nonprescription drug market;</content>
</clause>
<clause class="indent3 fontsize10" id="d3355e27677" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/b/1/D/iii" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iii">(iii) </num><content>the impact of such provision on competition in the nonprescription drug market;</content>
</clause>
<clause class="indent3 fontsize10" id="d3355e27684" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/b/1/D/iv" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iv">(iv) </num><content>the impact of such provision on consumer access to nonprescription drug products;</content>
</clause>
<clause class="indent3 fontsize10" id="d3355e27691" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/b/1/D/v" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="v">(v) </num><content>the impact of such provision on the prices of nonprescription drug products; and</content>
</clause>
<clause class="indent3 fontsize10" id="d3355e27699" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/b/1/D/vi" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="vi">(vi) </num><content>whether the administrative orders initiated by requestors under such section 505G have been sufficient to encourage the development of nonprescription drug products that would likely not be otherwise developed, or developed in as timely a manner; and</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" id="d3355e27707" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/b/1/E" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="E">(E) </num><content>whether the administrative orders initiated by requestors under such section 505G have been sufficient incentive to encourage innovation in the nonprescription drug market; and</content>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" id="d3355e27715" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/b/2" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">(2) </num><chapeau>an analysis of the impact of exclusivity under such section 586C for sunscreen ingredients, including—</chapeau><subparagraph class="indent2 fontsize10" id="d3355e27720" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/b/2/A" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">(A) </num><content>the number of sunscreen ingredients that were granted exclusivity and the specific ingredient that was determined to be generally recognized as safe and effective;</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" id="d3355e27727" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/b/2/B" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">(B) </num><content>whether, and to what extent, the exclusivity impacted the requestor’s or sponsor’s decision to develop the sunscreen ingredient;</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" id="d3355e27734" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/b/2/C" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="C">(C) </num><content>whether, and to what extent, the sunscreen ingredient granted exclusivity had previously been available outside of the United States;</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" id="d3355e27741" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/b/2/D" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="D">(D) </num><chapeau>an analysis of the implementation of the exclusivity provision in such section 586C, including—</chapeau><clause class="indent3 fontsize10" id="d3355e27746" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/b/2/D/i" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">(i) </num><content>the resources used by the Food and Drug Administration;</content>
</clause>
<clause class="indent3 fontsize10" id="d3355e27753" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/b/2/D/ii" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">(ii) </num><content>the impact of such provision on innovation, as well as research and development in the sunscreen market;</content>
</clause>
<clause class="indent3 fontsize10" id="d3355e27760" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/b/2/D/iii" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iii">(iii) </num><content>the impact of such provision on competition in the sunscreen market;</content>
</clause>
<clause class="indent3 fontsize10" id="d3355e27767" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/b/2/D/iv" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iv">(iv) </num><content>the impact of such provision on consumer access to sunscreen products;</content>
</clause>
<clause class="indent3 fontsize10" id="d3355e27774" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/b/2/D/v" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="v">(v) </num><content>the impact of such provision on the prices of sunscreen products; and</content>
</clause>
<clause class="indent3 fontsize10" id="d3355e27782" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/b/2/D/vi" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="vi">(vi) </num><content>whether the administrative orders initiated by requestors under such section 505G have been utilized by sunscreen ingredient sponsors and whether such process has been sufficient to encourage the development of sunscreen ingredients that would likely not be otherwise developed, or developed in as timely a manner; and</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" id="d3355e27790" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/b/2/E" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="E">(E) </num><content>whether the administrative orders initiated by requestors under such section 586C have been sufficient incentive to encourage innovation in the sunscreen market.</content>
</subparagraph>
</paragraph>
</subsection>
<subsection class="indent0 fontsize10" id="d3355e27799" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/c" role="instruction" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="c">(c) </num><heading><inline class="small-caps">Conforming Amendment</inline>.—</heading><chapeau>Section 751(d)(1) of the Federal Food, Drug, and Cosmetic Act (<a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section379r&amp;num=0&amp;edition=prelim" target="_blank"><ref href="/us/usc/t21/s379r/d/1">21 U.S.C. 379r(d)(1)</ref></a>) <amendingAction type="amend">is amended</amendingAction>—</chapeau><paragraph class="indent1 fontsize10" id="d3355e27814" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/c/1" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">(1) </num><chapeau>in the matter preceding subparagraph (A)—</chapeau><subparagraph class="indent2 fontsize10" id="d3355e27819" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/c/1/A" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">(A) </num><content>by <amendingAction type="delete">striking</amendingAction> “<quotedText>final regulation promulgated</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>final order under section 505G</quotedText>”; and</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" id="d3355e27832" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/c/1/B" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">(B) </num><content>by <amendingAction type="delete">striking</amendingAction> “<quotedText>and not misbranded</quotedText>”; and</content>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" id="d3355e27843" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptI/s3851/c/2" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">(2) </num><content>in subparagraph (A), by <amendingAction type="delete">striking</amendingAction> “<quotedText>regulation in effect</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>regulation or order in effect</quotedText>”.</content>
</paragraph>
</subsection>
</section>
            </p>
        </div>  
    </body>